Covaxin:  DCGI  approves Covaxin for kids aged between 2-18 years
Covaxin: DCGI approves Covaxin for kids aged between 2-18 years

New Delhi: In a major boost up to India's fight against COVID-19, the Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's Covaxin for children aged between 2-18 years. Covaxin, notably, has become the country's first COVID-19 vaccine that can be administered to children. 

This development came after Hyderabad-based Bharat Biotech had completed Phase-II and Phase-III trials of Covaxin in September on children below 18 years of age. The company had submitted the trial data to the DCGI  earlier this month. 

DCGI  said, “After detailed deliberation, the committee recommended for grant of market authorization" to children in age group of 2-18 years.  It added that "The emergency use authorisation, however, is subject to certain conditions. The developer of Covaxin will continue the study as per Whole Virion, Inactivated Corona Virus Vaccine the approved clinical trial protocol."

An AIIMS professor has recently claimed that the latest trials show that the safety and immunogenicity of Covaxin are almost the same in kids, as adults above 18 years of age. Dr Sanjay K Rai, a professor at the Centre for Community Medicine, AIIMS


WHO panel recommends COVID vaccine booster shot for people with weak immunity

India's cumulative COVID vaccination coverage surpasses 95.89 cr

Thailand to reopen to vaccinated visitors from next month: PM


Related News
Join NewsTrack Whatsapp group